Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Researchers Reverse Autism-Related Behaviors in Mice by Targeting Brain Blood Vessels (opens in a new tab)

scitechdaily.com · 2026-10-07

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 1 supported
  • 5 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

The one claim we could check holds up. One of six claims matches the study. This overall rating is based only on the claims we could check. Five claims the study doesn't address.

  • 1 supported
  • 5 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6Not coveredResearchers reversed several autism-related behavioral symptoms in adult mice by correcting a problem in the blood vessels that supply the brain.View evidenceHide evidence

Why this verdict

The abstract supports that P2Y2 activation restored cerebrovascular measures and rescued mouse behaviors, but it does not provide enough detail to verify the story’s fuller framing: that the rescue occurred specifically in adult mice, that several specific behavioral symptoms were reversed, or that correcting blood-vessel dysfunction was established as the causal mediator of the behavioral rescue. These may be addressed in the full paper, but they are not verifiable from the abstract-level profile.

1

Study evidence

Activation of P2Y2 receptors restored cerebrovascular reactivity in arterioles from 16p11.2‑deficient mice in an ex vivo preparation (statement reported in abstract).

“Activating P2Y2 receptors restored cerebrovascular reactivity in 16p11.2-deficient arterioles ex vivo”
2

Study evidence

Activation of P2Y2 receptors restored activity-dependent cerebral blood flow in vivo in 16p11.2-deletion mice (reported in the abstract).

“Activating P2Y2 receptors restored ... activity-dependent cerebral blood flow in vivo”
Claim 2 of 6Not coveredThe study, published in Neuron, focused on mice carrying a 16p11.2 deletion, a genetic change associated with autism in humans.View evidenceHide evidence

Why this verdict

The profile supports that the paper studied 16p11.2-deletion mice as an ASD-relevant mouse model. However, the supplied abstract-level profile does not itself verify the bibliographic claim that the study was published in Neuron, nor does it explicitly detail the human genetic-association evidence for 16p11.2 deletion beyond the ASD-model context.

1

Study evidence

The 16p11.2 deletion causes a selective bioenergetic failure in brain endothelial cells, evidenced by reduced intracellular ATP levels in endothelial cells from 14-day-old and adult male mice compared with wild-type.

“Using 14-day-old and adult 16p11.2-deficient and wild-type male mice, we now show that the 16p11.2 deletion causes a bioenergetic failure selectively in endothelial cells (ECs) with reduced intracellular ATP levels.”
2

Study evidence

Activation of P2Y2 receptors rescued 16p11.2 deletion–associated mouse behaviors (abstract statement).

“Activating P2Y2 receptors ... rescued 16p11.2 deletion-associated mouse behaviors.”
Claim 3 of 6Not coveredActivating a receptor called P2Y2 restored blood vessel function, increased blood flow in the brain, and reversed hyperactivity, repetitive movements, and impaired motor learning in the animals.View evidenceHide evidence

As statedseveral behavioral abnormalities

Why this verdict

The abstract-level profile supports P2Y2 activation restoring cerebrovascular reactivity ex vivo, restoring activity-dependent cerebral blood flow in vivo, and rescuing 16p11.2 deletion–associated mouse behaviors. But it does not specify the particular behavioral domains listed by the story—hyperactivity, repetitive movements, and impaired motor learning—or provide enough detail to verify that each was reversed. The vascular portion is supported; the named behavioral details are not verifiable at abstract depth.

1

Study evidence

Activation of P2Y2 receptors restored cerebrovascular reactivity in arterioles from 16p11.2‑deficient mice in an ex vivo preparation (statement reported in abstract).

“Activating P2Y2 receptors restored cerebrovascular reactivity in 16p11.2-deficient arterioles ex vivo”
2

Study evidence

Activation of P2Y2 receptors restored activity-dependent cerebral blood flow in vivo in 16p11.2-deletion mice (reported in the abstract).

“Activating P2Y2 receptors restored ... activity-dependent cerebral blood flow in vivo”
Claim 4 of 6Not coveredThe researchers used a drug that activates P2Y2, and the compound is already approved in Japan and South Korea for dry eye syndrome.View evidenceHide evidence

Why this verdict

The profile supports P2Y2 receptor activation as the intervention concept, but the abstract-level evidence does not identify the specific drug or compound, its regulatory status, or approval in Japan and South Korea for dry eye syndrome. Those details cannot be checked from the supplied paper profile.

1

Study evidence

In vitro ATP supplementation (intra- or extracellular) rescued functional deficits in 16p11.2-deficient endothelial cells via activation of P2 purinergic receptors, specifically implicating P2Y2.

“Intra- or extracellular ATP supplementation rescued the function of 16p11.2-deficient ECs in vitro via P2 purinergic receptor activation, specifically P2Y2 receptors.”
2

Study evidence

Activation of P2Y2 receptors restored cerebrovascular reactivity in arterioles from 16p11.2‑deficient mice in an ex vivo preparation (statement reported in abstract).

“Activating P2Y2 receptors restored cerebrovascular reactivity in 16p11.2-deficient arterioles ex vivo”
Claim 5 of 6Not coveredThe team plans to test whether activating P2Y2 earlier in development produces different or additional effects.View evidenceHide evidence

Why this verdict

The supplied paper profile does not report researchers’ future plans to test earlier developmental P2Y2 activation. This may come from interviews or article reporting outside the paper abstract, but it is not verifiable from the provided paper evidence.

Claim 6 of 6SupportedA study in mice suggests that cells lining the brain’s blood vessels may play an important role in autism-related symptoms.View evidenceHide evidence

Why this verdict

The abstract-level profile supports a hedged mouse-model claim that brain endothelial cells may be important in ASD-relevant phenotypes: 16p11.2 deletion caused endothelial bioenergetic failure, P2Y2 activation restored cerebrovascular function, and P2Y2 activation rescued 16p11.2 deletion–associated mouse behaviors. The story’s wording is appropriately framed as a suggestion from mice, not a human clinical finding.

1

Study evidence

The 16p11.2 deletion causes a selective bioenergetic failure in brain endothelial cells, evidenced by reduced intracellular ATP levels in endothelial cells from 14-day-old and adult male mice compared with wild-type.

“Using 14-day-old and adult 16p11.2-deficient and wild-type male mice, we now show that the 16p11.2 deletion causes a bioenergetic failure selectively in endothelial cells (ECs) with reduced intracellular ATP levels.”
2

Study evidence

Activation of P2Y2 receptors restored activity-dependent cerebral blood flow in vivo in 16p11.2-deletion mice (reported in the abstract).

“Activating P2Y2 receptors restored ... activity-dependent cerebral blood flow in vivo”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The abstract lacks quantitative effect sizes, sample sizes, statistical details, behavioral assay details, and P2Y2 agonist dose/route/timing information.

    The story does not mention that the abstract-level evidence leaves key methodological and quantitative details unspecified, which limits independent appraisal of the strength and scope of the reported rescues.

    From In vitro endothelial-cell rescue assay; Ex vivo arteriolar reactivity assay; In vivo CBF measurement during activity/sti

  • The profile does not specify whether behavioral rescue was assessed across ages or limited to a particular age group.

    The story frames some effects as occurring in adult mice and mentions future earlier-development testing, but the abstract-level paper profile does not verify the age timing for the behavioral rescue.

    From in_vivo animal behavioral experiments (pharmacologic P2Y2 activation)

6 things the story did carry across
  • The paper reports a selective bioenergetic failure in brain endothelial cells of 16p11.2-deficient male mice, with reduced intracellular ATP at postnatal and adult ages.
  • ATP supplementation rescued functional deficits in 16p11.2-deficient endothelial cells in vitro through purinergic signaling, specifically P2Y2 receptor activation.
  • P2Y2 receptor activation restored cerebrovascular reactivity ex vivo in 16p11.2-deficient arterioles.
  • P2Y2 receptor activation restored activity-dependent cerebral blood flow in vivo in 16p11.2-deletion mice.
  • P2Y2 receptor activation rescued 16p11.2 deletion–associated mouse behaviors, but the abstract-level profile does not specify which behavioral assays or domains were rescued.
  • The evidence is from a mouse genetic model and does not establish efficacy or safety in humans.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroATP supplementation rescues functional deficits in 16p11.2-deficient endothelial cells in vitro via purinergic signaling, specifically P2Y2 receptor activation.In vitro endothelial-cell rescue assayExpand

In plain English

In cultured endothelial cells derived from 16p11.2-deficient mice, intra- or extracellular ATP supplementation restored endothelial cell function in vitro; the rescue was attributed to activation of P2 purinergic receptors with specificity reported for P2Y2.

Key findings

  • In vitro ATP supplementation (intra- or extracellular) rescued functional deficits in 16p11.2-deficient endothelial cells via activation of P2 purinergic receptors, specifically implicating P2Y2.
“Intra- or extracellular ATP supplementation rescued the function of 16p11.2-deficient ECs in vitro via P2 purinergic receptor activation, specifically P2Y2 receptors.”
What this piece can’t prove
  • The unit covers only in vitro findings; how these cellular-level rescues relate mechanistically to ex vivo or in vivo outcomes is addressed elsewhere in the paper but not within this in vitro appraisal unit.

1 further detail could not be confirmed from the summary.

2in vivo animal16p11.2 deletion causes a selective bioenergetic failure in brain endothelial cells (reduced intracellular ATP) across postnatal and adult male mice.Comparative in vivo genetic mouse study (16p11.2 deletion vs wild-type) with cell-type ATP measurementExpand

In plain English

In 14-day-old and adult male 16p11.2-deletion mice versus wild-type controls, the 16p11.2 deletion is reported to produce a selective bioenergetic failure in brain endothelial cells, evidenced by reduced intracellular ATP levels.

Key findings

  • The 16p11.2 deletion causes a selective bioenergetic failure in brain endothelial cells, evidenced by reduced intracellular ATP levels in endothelial cells from 14-day-old and adult male mice compared with wild-type.
“Using 14-day-old and adult 16p11.2-deficient and wild-type male mice, we now show that the 16p11.2 deletion causes a bioenergetic failure selectively in endothelial cells (ECs) with reduced intracellular ATP levels.”
What this piece can’t prove
  • Findings are from a mouse genetic model (male mice) and do not address translation to humans or female animals.

2 further details could not be confirmed from the summary.

3ex vivo animalP2Y2 receptor activation restores cerebrovascular function ex vivo and in vivo in 16p11.2-deficient mice.Ex vivo arteriolar reactivity assayExpand

In plain English

In ex vivo isolated arterioles from 16p11.2‑deletion (16p11.2‑deficient) mice, activation of P2Y2 purinergic receptors restored cerebrovascular (arteriolar) reactivity.

Key findings

  • Activation of P2Y2 receptors restored cerebrovascular reactivity in arterioles from 16p11.2‑deficient mice in an ex vivo preparation (statement reported in abstract).
“Activating P2Y2 receptors restored cerebrovascular reactivity in 16p11.2-deficient arterioles ex vivo”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4in vivo animalP2Y2 receptor activation restores cerebrovascular function ex vivo and in vivo in 16p11.2-deficient mice.In vivo CBF measurement during activity/stimulation in 16p11.2-deletion mice with P2Y2 receptor activationExpand

In plain English

In 16p11.2-deletion mice, activation of P2Y2 purinergic receptors restored activity-dependent cerebral blood flow measured in vivo (abstract statement). The study reports an in vivo physiology endpoint distinct from ex vivo vessel assays and behavior, but the abstract does not provide technical or quantitative details for the cerebral blood flow measurement or the P2Y2 activation protocol.

Key findings

  • Activation of P2Y2 receptors restored activity-dependent cerebral blood flow in vivo in 16p11.2-deletion mice (reported in the abstract).
“Activating P2Y2 receptors restored ... activity-dependent cerebral blood flow in vivo”
What this piece can’t prove
  • It is not specified whether the reported rescue was observed in all tested ages or only a specific age group.

2 further details could not be confirmed from the summary.

5in vivo animalP2Y2 receptor activation rescues autism-relevant behaviors in 16p11.2 deletion mice, supporting purinergic engagement as a therapeutic avenue.in vivo animal behavioral experiments (pharmacologic P2Y2 activation)Expand

In plain English

In a 16p11.2 deletion mouse model of ASD, activation of P2Y2 purinergic receptors rescued 16p11.2 deletion–associated mouse behaviors, as reported in the abstract.

Key findings

  • Activation of P2Y2 receptors rescued 16p11.2 deletion–associated mouse behaviors (abstract statement).
“Activating P2Y2 receptors ... rescued 16p11.2 deletion-associated mouse behaviors.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

Candidate

Author response for "Ink unveiled: the histopathology of benign core biopsy specimens from axillary lymph nodes with tattoo pigment"

2026 · Crossref

Source (opens in a new tab)
Candidate

Author response for "Poly(Trehalose Methacrylate) Enhances Immobilized Alcalase Performance on Silica Microparticles"

2026 · Crossref

Source (opens in a new tab)

And 28 more candidates considered.